HUBBALLI TIMES NEWS DESK
DHARWAD: People of the twin cities have a reason to cheer up as a city-based firm entered into an agreement to manufacture Sputnik V, a single dose Covid-19 vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology of Russia.
Shilpa Biologicals Private Limited (SBPL) will manufacture the vaccine at its production centre in Belur Industrial Area on the outskirts of Dharwad. It will be among the first production units of Sputnik V in India.
The SBPL has entered into a three year agreement with Hyderabad’s Dr. Reddy’s to manufacture Sputnik V vaccine from its integrated biologics research and development cum manufacturing centre which is a huge unit spread over 44,000 sqm in Dharwad. This Centre of SBPL has latest equipment to produce vaccines, drugs and other medical components.
According to company, production of 50 million doses of the dual vector Sputnik V in the first 12 months is the target given for the company.
As per the agreement, Dr Reddy’s will facilitate transfer of technology to the Dharwad company. The vaccine doses will be marketed and distributed by the Dr Reddy’s Laboratory which has distribution rights in India.
According to a report, Dr. Reddy’s has tied up with Apollo Hospitals for the vaccination drive across the country, starting with Hyderabad.
Until now, two vaccines – Covidshield and Covaxin – are being used to vaccinate people in the country. Sputnik V will be the third vaccine that will be available for the public.